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A B S T R A C T
13C Magnetic Resonance Spectroscopy (MRS) using hyperpolarized 13C-labeled pyruvate as a substrate oﬀers a
measure of pyruvate-lactate interconversion and is thereby a marker of the elevated aerobic glycolysis (Warburg
eﬀect) generally exhibited by cancer cells. Here, we aim to compare hyperpolarized [1-13C]pyruvate MRS with
simultaneous 18F-2-ﬂuoro-2-deoxy-D-glucose (FDG) PET in a cross-sectional study of canine cancer patients.
Methods: Canine cancer patients underwent integrated PET/MRI using a clinical whole-body system.
Hyperpolarized [1-13C]pyruvate was obtained using dissolution-DNP. 18F-FDG PET, dynamic 13C MRS, 13C MRS
Imaging (MRSI) and anatomical 1H MRI was acquired from 17 patients. Apparent pyruvate-to-lactate rate
constants were estimated from dynamic 13C MRS. 18F-FDG Standard Uptake Values and maximum [1-13C]lac-
tate-to-total-13C ratios were obtained from tumor regions of interest. Following inspection of data, patients were
grouped according to main cancer type and linear regression between measures of lactate generation and 18F-
FDG uptake were tested within groups. Between groups, the same measures were tested for group diﬀerences.
Results: The main cancer types of the 17 patients were sarcoma (n= 11), carcinoma (n=5) and mastocytoma
(n=1). Signiﬁcant correlations between pyruvate-to-lactate rate constants and 18F-FDG uptake were found for
sarcoma patients, whereas no signiﬁcant correlations appeared for carcinoma patients. The sarcoma patients
showed a non-signiﬁcant trend towards lower 18F-FDG uptake and higher lactate generation than carcinoma
patients. However, the ratio of lactate generation to 18F-FDG uptake was found to be signiﬁcantly higher in
sarcoma as compared to carcinoma. The results were found both when lactate generation was estimated as an
apparent pyruvate-to-lactate rate constant from dynamic 13C MRS and as an [1-13C]lactate to total 13C ratio from
13C MRSI.
Conclusions: A comparison of hyperpolarized [1-13C]pyruvate MRS with simultaneous 18F-FDG PET indicate that
lactate generation and 18F-FDG uptake in cancers can be related and that their relation depend on cancer type.
This ﬁnding could be important for the interpretation and eventual clinical implementation of hyperpolarized
13C. In addition, the diﬀerences between the two modalities may allow for better metabolic phenotyping per-
forming hybrid imaging in the form of hyperPET.
1. Introduction
Clinical imaging of cancer has during the last decades witnessed
morphological imaging modalities such as CT and MRI being supple-
mented and augmented by molecular imaging of tumor function [1–3].
PET oﬀers whole-body functional imaging and 18F-2-ﬂuoro-2-deoxy-D-
glucose (18F-FDG) PET often in combination with diagnostic CT, is a
widely used clinical tool for detection of cancer, staging and assessment
of response to therapy [4–6]. FDG is a glucose analog, which is trans-
ported into cells and trapped as FDG-6-phosphate. The 18F FDG uptake
is a measure of regional glucose uptake and thereby an indirect marker
of the elevated aerobic glycolysis, Warburg eﬀect, generally exhibited
by cancer cells [7,8].
Magnetic Resonance Spectroscopy (MRS) can also characterize
cancer metabolism [9] and enabled by the development of dissolution
Dynamic Nuclear Polarization (d-DNP) [10,11], hyperpolarized 13C
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MRS has reached clinical accessibility. In particular, 13C MRS Imaging
(MRSI) of prostate cancer using hyperpolarized 13C-labeled pyruvate as
a substrate has been demonstrated in patients [12]. Here, the elevated
aerobic glycolysis can be measured through the appearance of the 13C-
lactate signal, and dynamic 13C MRS can provide an estimate of the
apparent pyruvate-to-lactate rate constant. The measured rate constant
is apparent since it is also aﬀected by e.g. expression of monocarboxylic
transporters in the cell membranes.
Accordingly, both 18F FDG PET and hyperpolarized 13C-pyruvate
MRS are molecular imaging modalities sensitive to glycolysis. However,
PET is well-established clinically while hyperpolarized MRS is still at its
infancy [11,13–15]. The relation between 18F FDG PET and hyperpo-
larized 13C-pyruvate MRS in cancer has been explored in a limited
number of preclinical studies using a sequential setup [13,16–18], fo-
cusing on feasibility [17] and treatment eﬀects [13,16,18]. With the
availability of integrated PET and MRI in a clinical, whole-body system
[19], simultaneous PET and hyperpolarized 13C MRS (hyperPET)
[20,21] is possible. We have recently demonstrated, in a series of 10
canine cancer patients, an overall spatial concordance of 13C-lactate
and 18F FDG uptake patterns [22], but have also observed canine cancer
patients with a spatial mismatch [23]. Cancer cells utilize both glyco-
lysis and oxidative phosphorylation for energy metabolism [8,24,25]
and the degree of glycolysis might be heterogeneous across cancer cell
types [24,26].
To further compare the two modalities of 18F FDG PET and hy-
perpolarized 13C-pyruvate MRS, we investigate in this study the relation
between 18F FDG uptake and apparent pyruvate-to-lactate rate constants
in a larger series of canine cancer patients with diﬀerent cancer types.
This allows us to compare 18F FDG PET and hyperpolarized 13C-pyruvate
MRS estimates of glycolysis in a cross-sectional study, with the very basic
hypothesis that tumor 18F FDG uptake and apparent pyruvate-to-lactate
rate constants are correlated and may depend on cancer type.
2. Materials and methods
2.1. Study population
Seventeen canine cancer patients with solid tumors were con-
secutively enrolled in the study. All patients underwent physical
examination as well as routine pre-anesthetic and diagnostic work up
laboratory evaluation. Inclusion criteria were diagnosis of malignant
tumor type and complete hyperPET data (18F-FDG PET, dynamic 13C
MRS and 13C MRSI). Exclusion criteria were clinical or laboratory work
up precluding anesthesia. All canine cancer patients underwent PET/
MRI with 18F FDG PET as part of their diagnostic and staging work-up
prior to therapy recommendation. Hyperpolarized 13C MRSI was per-
formed concomitantly. The owners gave informed consent and the
study was approved by the Ethics and Administrative Committee,
Department of Veterinary Clinical Sciences, Faculty of Health and
Medical Sciences, University of Copenhagen.
2.2. Experimental setup
PET/MRI was performed using an integrated system (Siemens
Biograph mMR) with a 3 T MR imager. 13C MRSI utilized a 1H/13C dual-
tuned transmit/receive surface ﬂex coil centered on the lesion, or (pa-
tient 16, Table 1), a 13C transmit/receive birdcage head coil (RAPID
Biomedical).
The canine patients were anesthetized using a bolus injection of
Propofol and maintained by administration of air/oxygen enriched gas
mixture with Sevoﬂurane. Heart rate, oxygenation, and blood pressure
were monitored throughout the scanning procedure.
Hyperpolarized [1-13C]pyruvate was obtained using dissolution-
DNP (SpinLab, GE Healthcare) using the procedure as described by
Gutte et al. [22]. The amount injected was 0.68mL/kg body weight of
250mM [1-13C]pyruvate.
2.3. 1H-MRI
Anatomical 1H MRI included T2 turbo spin echo (tse) [repetition
time (TR) 4000ms, echo time (TE) 89ms, pixel size 0.6× 0.5mm2, 19
slices of 3mm thickness] in 3 planes. A single slice T2-tse angulated and
centered as the 13C MRSI was obtained as a geometrical reference. In
most patients, the exam included transverse fat saturated T1-tse [TR
550ms, TE 6.5 ms, pixel size 0.7× 0.6mm2, 27 slices of 3mm thick-
ness] following gadolinium injection (0.1 mL/kg Gadovist).
Table 1
Summary of patient characteristics.
patient weight PET p.i. time Tumor location Tumor tissue type Grade Classif. based on
[kg] [min]
1 15 42 Subcutaneous, face Soft tissue sarcoma (Fibrosarcoma) inter-mediate Histo-pathology
2 42 41 Posterior paw Soft tissue sarcoma 1 Histo-pathology
3 46 48 Nasal cavity Squamous cell carcinoma ÷ Histo-pathology
4 50 26 Maxilla Soft tissue sarcoma (Fibrosarcoma) low Histo-pathology
5 29 30 Nasal cavity Chondrosarcoma 1 Histo-pathology
6 22 32 Scapula Osteosarcoma – telangiectatic 2 Histo-pathology
7 13 39 Spine and axilla Soft tissue sarcoma (pro peripheral nerve sheath) 2 Histo-pathology
8 21 78 Femur Osteosarcoma – medullary low Histo-pathology
9 32 58 Thyroid Carcinoma, follicular n.r. Histo-pathology
10 39 65 Axilla Unspeciﬁed Sarcoma ÷ Cytology*
11 27 55 Thyroid Adenocarcinoma – producing n.r. Histo-pathology
12 24 55 Thyroid Carcinoma – C-cell n.r. Histo-pathology
13 19 60 Thyroid Carcinoma, follicular n.r. Histo-pathology
14 48 61 Knee Mastocytoma 2 Histo-pathology
15 33 58 Subcutaneous, thoracic wall Soft tissue sarcoma 1 Histo-pathology
16 31 57 Trigeminal nerve Pro soft tissue sarcoma – peripheral nerve sheath ÷ Imaging ﬁndings†
17 8 59 Maxillla Soft tissue sarcoma (Fibrosarcoma) low Histo-pathology
n.r.: no relevant.
÷: not available.
* : The histopathological sample contained muscle cells only. Cytology showed malignantmesenchymal tumor cells, identifying the tumor as an unspeciﬁed
sarcoma.
† : Initial diagnosis based on MRI ﬁndings prior to referral indicated neoplasia of the right trigeminal/mandibular nerve – most likely peripheral nerve sheath
tumor (sarcoma). FDG-PET is consistent with neoplasia.
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2.4. 18F-FDG PET
PET was performed as a single-bed, 5min acquisition, 30min or
60min post injection (p.i.) of 8 MBq/kg 18F FDG.
Image reconstruction used 3D OP-OSEM with 4 iterations, 21 sub-
sets, matrix 344×344, 4mm 3D Gaussian post-ﬁlter and voxel size
2.1×2.1×2.0mm3. Attenuation correction (AC) utilized vendor
supplied algorithm, however in some cases a faulty segmentation of the
AC map was observed due to sensitivity proﬁle of the MR surface coil,
in which case a semi-automatic delineation of body contours to correct
the AC map was performed based on the non-AC PET. 18F FDG uptake
was reported as standardized uptake values (SUV).
2.5. 13C-MRS
Calibration of the 13C MR ﬂip angle was performed using an urea
phantom [21].
Dynamic 13C MRS [TR 1000ms, TE 0.757ms, ﬂip angle 5°, band-
width 4000 Hz, 180 repetitions, starting upon hyperpolarized 13C-pyr-
uvate injection] was recorded in an axially/oblique oriented 40mm
thick volume centered on and in most cases covering the entire tumor.
The location of the volume was documented for the purpose of PET
Region Of Interest (ROI) drawing.
13C-MRSI employed 2D chemical shift imaging and was acquired
30–50 s p.i. of hyperpolarized [1-13C]pyruvate [TR 80ms, ﬂip angle
θ=10°, bandwidth 10,000 Hz, slice thickness 13–23mm, matrix
16×16, pixel size ranging from 5×5mm2 to 12.5×12.5 mm2 and
total imaging time 11 s]. Field-of-View was adjusted according to the
body part of interest and planned through the central part of the tumor.
The acquisition delay was chosen to obtain maximum 13C-lactate signal
based on the previous dynamic 13C MRS acquisition. 13C MRSI was
obtained during or subsequent to PET.
2.6. Post processing of 13C MRS
Peak areas of [1-13C]pyruvate, [1-13C]lactate, [1-13C]alanine and
[1-13C]pyruvate hydrate were quantiﬁed using a general linear model
implemented in MatLab (Mathworks) and applied in the time domain.
For the dynamic 13C MRS, an apparent pyruvate-to-lactate rate
constant kPL was calculated as kPL= rL×AUC(lactate)/AUC(pyruvate),
with the constant rL=T1−1− TR−1× ln(cos(θ)) [27,28]. AUC refers
to the area under the time series of the metabolite. T1 was ﬁxed at 20 s.
Pyruvate delivery was characterized measuring Time To Peak (TTP) as
well as Time To Initiation of the time series.
Concerning single time point 13C MRSI, the metabolite ratio of
lactate to all modeled peak heights (total Carbon) was calculated for all
voxels which had both a lactate and a pyruvate peak height larger than
5 times the standard deviation of the noise in a background region of
the spectrum. Ratio images were converted to DICOM for later ROI
analysis.
2.7. ROI deﬁnition
Two sets of tumor PET ROIs were deﬁned corresponding to the
dynamic 13C MRS acquisition and single time point 13C MRSI, respec-
tively.
The ROI corresponding to dynamic 13C MRS was delineated based
on a 50% of SUVmax iso-contour in Mirada XD (version 1.2.0.59, Mirada
Medical) and limited to the 13C MRS volume in case the volume did not
cover the entire tumor. FDG uptake of non-neoplastic origin corre-
sponding to e.g. muscle, joints, or nasal mucous membrane was re-
moved. SUVmean, SUVmax and ROI volume were recorded.
For the single time point 13C MRSI, PET was resampled to the 2D
imaging plane of the 13C MRSI in OsiriX (version 4.1.2, PIXMEO) and
the tumor was delineated as above. SUV_2Dmax and the maximum
lactate ratio LactateRatiomax were recorded.
2.8. Comparison of 18F FDG PET and hyperpolarized 13C MRS
To explore the relation of FDG uptake and pyruvate-to-lactate in-
terconversion, linear regression was tested for SUVmean, SUVmax and 3D
ROI volume versus kPL, as well as SUV_2Dmax versus LactateRatiomax.
Further, the ratios kPL/SUVmean,max and LactateRatiomax/SUV_2Dmax
were calculated for each lesion. Patients were grouped according to
main cancer type following inspection of data. Group diﬀerences were
assessed using a 2-sample unpaired t-test. A p-value of 0.05 was con-
sidered signiﬁcant.
3. Results
3.1. Patients
Seventeen canine cancer patients were included. Six patients had
PET acquired nominally 30min p.i. (all sarcoma), and 11 patients
60min p.i. (patient 3 had PET delayed to 48min p.i and was included in
the 60min p.i. group). Cancer types included seven soft tissue (ST)
sarcomas, four thyroid carcinomas, two osteosarcomas, one chon-
drosarcoma, one unspeciﬁed sarcoma, one mastocytoma and one
squamous cell (SC) carcinoma. Tumor classiﬁcation was based on his-
topathology except for patient 10 and 16, which were diagnosed by
cytology and combined clinical and imaging ﬁndings, respectively
(Table 1).
3.2. Patient examples
Fig. 1 shows a patient with a large thyroid carcinoma and Fig. 2 a
patient with a ﬁbrosarcoma extending from the maxilla to behind the
left eye. The tumors exhibited FDG uptake [subﬁgures a) and c)] as well
as lactate signal both during dynamic 13C MRS [subﬁgures b)] and with
single time point 13C MRSI [subﬁgures d)].
3.3. Comparison of apparent lactate generation and 18F FDG uptake
The apparent pyruvate-to-lactate rate constant kPL obtained from all
canine patients varied by a factor of more than 10. Fig. 3a)–c) shows
SUVmean, SUVmax and Volume from the 3D ROI as function of kPL.
Cancer type is denoted in the legend of Fig. 3a). There is clearly no
correlation between apparent pyruvate-to-lactate rate constants and 18F
FDG uptake across patients with all cancer types, Fig. 3a)–b). Upon
closer inspection, two main qualitative features can be seen im-
mediately: 1) The sarcoma patients tend to show a linear relation be-
tween SUV and kPL across patients, both for PET data obtained 30min
p.i. (ﬁlled grey symbols) and 60min p.i. (ﬁlled black symbols). The
trend is observed across sarcoma cancer subtypes. No linear trend ap-
pears for carcinoma patients. 2) In the group of patients with sarcoma,
patients appear to have a combination of lower SUV and higher kPL than
the carcinoma (open triangles and square). Of further note, the mas-
tocytoma (open diamond) appears to group with the sarcoma patients.
The tumor volume appears unrelated to kPL. The qualitative trends 1)-2)
are replicated by the 2D measurements of maximum lactate ratio and
SUV_2Dmax in the 13C MRSI imaging plane shown in Fig. 4.
Results of testing for linear trends between 18F FDG uptake and
lactate generation across patients are shown in Table 2 conﬁrming the
qualitative impressions above. Signiﬁcant slopes appear for kPL versus
SUVmax (sarcomas 30 and 60min p.i.), kPL versus SUVmean (sarcomas
60min p.i.) and LactateRatiomax versus SUV_2Dmax (sarcomas 60min
p.i.). Also, kPL versus SUVmean (sarcomas 30min p.i.) is close to sig-
niﬁcance (p=0.064). No linear relation involving the group of carci-
nomas is signiﬁcant; neither is the relation of kPL and tumor volume. No
oﬀsets are signiﬁcant for any of the linear trends tested. Regression
lines for signiﬁcant correlations are included in Figs. 3 and 4.
The qualitative impression that sarcoma patients showed a combi-
nation of higher apparent lactate generation and lower 18F FDG uptake
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than sarcoma patients was tested by comparing ratios of apparent
pyruvate-to-lactate rate constant kPL to SUVmean and SUVmax and like-
wise the ratio of LactateRatiomax to SUV_2Dmax in patients with 18F FDG
PET obtained 60min p.i. Results are shown in Table 3 Fig. 5. The ratios
kPL/SUVmean and kPL/SUVmax were signiﬁcantly higher (on average by a
factor of approximately 3, p=0.001 and 0.003) in the group of sar-
coma patients as compared to the carcinoma patients. The tendencies to
higher kPL and a lower SUVmean,max in sarcoma as compared to
carcinoma were not statistically signiﬁcant. Also, the ratio LactateR-
atiomax/SUV_2Dmax was signiﬁcantly higher (on average by a factor of
approximately 3, p= 0.001) in the group of sarcoma patients as com-
pared to the carcinoma patients (Fig. 5).
Pyruvate TTP was 24.9 ± 6.6 s. TTP, TTI and TTP-TTI were not
signiﬁcantly diﬀerent between groups of sarcoma and carcinoma pa-
tients.
Fig. 2. Sarcoma patient example.
Figure shows patient 17 (Table 1). 18F FDG PET in a) sagittal and b) coronal orientation with 3D ROI (outlined in orange color) and c) fused with T2-tse MRI. d)
Pyruvate (blue) and lactate (red, multiplied by 10) peak areas. e) 18F FDG PET in the transverse/oblique orientation of the 13C MRSI plane with 2D ROI (outlined in
green color) and f) fused with T2-tse MRI. g) Lactate ratio from 13C MRSI fused with T2-tse MRI and h) T2-tse MRI.
Fig. 1. Carcinoma patient example.
Figure shows patient 9 (Table 1). 18F FDG PET in a) coronal orientation with 3D ROI (outlined in orange) and b) fused with T2-tse MRI. c) Pyruvate (blue) and lactate
(red, multiplied by 10) peak areas as function of time from injection of hyperpolarized pyruvate. d) 18F FDG PET in the transverse orientation of the 13C MRSI plane
with 2D ROI (outlined in green) and e) fused with T2-tse MRI. f) Lactate ratio from 13C MRSI fused with T2-tse MRI and g) T2-tse MRI.
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4. Discussion
The study compared measurements of elevated aerobic glycolysis by
means of 18F FDG PET and hyperpolarized [1-13C]pyruvate MRS in a
series of canine patients with solid tumors of diﬀerent tissue types. The
combination of pyruvate-to-lactate rate constants and 18F FDG uptake
appeared to group patients according to main cancer types. Thus, the
ratio of apparent pyruvate-to-lactate rate constant to 18F FDG uptake
was found to be signiﬁcantly higher in sarcoma as compared to carci-
noma. Pyruvate-to-lactate rate constants and 18F FDG uptake correlated
well across patients in the sarcoma patient group, but not in the car-
cinoma patient group. Those results indicate that while lactate gen-
eration and 18F FDG uptake in cancers can be related, their relation
depends on cancer tissue type. This ﬁnding could be important for the
interpretation and eventual clinical implementation of hyperpolarized
Fig. 3. Correlation of FDG uptake and lactate generation.
Figure shows tumor 18F FDG uptake quantiﬁed as SUVmean
(subﬁgure a), SUVmax (subﬁgure b) and ROI Volume (sub-
ﬁgure c) versus apparent pyruvate-to-lactate transfer coeﬃ-
cient kPL. Cancer types are explained in the legend (subﬁgure
a). Lines show linear trends for signiﬁcant correlations within
main cancer types (sarcoma and carcinoma) (see Table 2).
Fig. 4. Correlation of FDG uptake and lactate generation, 2D ROI.
Figure shows tumor SUV_2Dmax in the 2D plane of the 13C MRSI versus max-
imum tumor lactate to pyruvate ratio, LactateRatiomax. Grouping of patients
and symbols used are the same as in Fig. 3, and are explained in the legend. The
line shows the linear trend for a signiﬁcant correlation in the group of sarcoma
patients (Table 2).
Table 2
Correlation of [1-13C]lactate generation and 18F FDG uptake.
Cancer type Sarcoma Carcinoma
Nominal PET uptake time
[p.i.]
30min (n= 6) 60min (n= 5) 60min (n=5)
Correlation of kPL and
SUVmax
p= 0.008*
R2=0.85
p=0.016*
R2= 0.89
p=0.37
R2= 0.21
Correlation of kPL and
SUVmean
p= 0.064
R2=0.62
p=0.011*
R2= 0.92
p=0.46
R2= 0.14
Correlation of kPL and
Volume
p=0.22
R2=0.35
p=0.13
R2= 0.77
p=0.19
R2= 0.38
Correlation of (Lac/
Pyr)max and SUVmax
p= 0.23
R2=0.27
p=0.033*
R2= 0.83
p=0.34
R2= 0.30
Uncorrected R2 values for linear regression are reported.
* P < 0.05.
Table 3
Group diﬀerences of [1-13C]lactate generation and 18F FDG uptake.
Carcinoma (n= 5) Sarcoma (n=5) Diﬀerence
kPL [s−1] (3.44 ± 2.20)*10−3 (6.52 ± 3.53)*10−3 p= 0.144
SUVmean [g/mL] 5.90 ± 2.35 3.52 ± 2.02 p=0.125
SUVmax [g/mL] 9.20 ± 3.60 5.60 ± 3.34 p=0.140
kPL/SUVmean
[s−1g−1mL]
(0.605 ± 0.305)*10−3 (1.82 ± 0.439)*10−3 p= 0.001*
kPL/SUVmax
[s−1g−1mL]
(0.384 ± 0.188)*10−3 (1.16 ± 0.317)*10−3 p= 0.003*
LactateRatiomax 0.215 ± 0.091 0.418 ± 0.188 p=0.075
SUV_2Dmax [g/
mL]
7.44 ± 3.46 4.64 ± 2.15 p=0.170
LactateRatiomax/
SUV_2Dmax
[g−1mL]
0.0314 ± 0.0143 0.0903 ± 0.0190 p=0.001*
All PET data are obtained nominally 60min p.i. Average values ± standard
deviations are reported.
* P < 0.05.
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13C pyruvate imaging.
Only a few earlier studies have compared 18F FDG PET and hy-
perpolarized [1-13C]pyruvate MRS in animal models [16,17], and using
sequential exams as opposed to simultaneous exams performed by us in
the combined PET/MR clinical system. In a study of murine lymphoma
treatment [16], a comparable decrease in 18F FDG uptake and pyruvate-
to-lactate exchange was found 24 h after chemotherapy, with the de-
crease in 18F FDG uptake appearing earliest. A recent treatment study
using an ovarian cancer mouse model showed increased pyruvate-to-
lactate conversion after chemotherapy without a change in 18F FDG
uptake [18]. There was no attempt to correlate 18F FDG uptake and 13C
MRS across animals in the abovementioned studies. In a study of he-
patocellular carcinoma tumor–bearing rats [17], tumors exhibited in-
creased 18F FDG uptake and locally increased pyruvate-to-lactate ex-
change. However, no correlation between PET and MRS data was
observed across animals, possibly corresponding to the lack of corre-
lation we observe for the canine carcinoma patients. Previous studies on
canine cancer patients from our group [20,22,23] focused on single
cases, feasibility and spatial concordance of 18F FDG PET and hy-
perpolarized [1-13C]pyruvate MRSI and did not compare data across
patients or cancer tissue types.
The apparent pyruvate-to-lactate rate constant reported here was
based on dynamic measurements performed in a 40mm thick slab en-
compassing the tumor but also surrounding tissues which may inﬂuence
rate constant estimates. This methodology is common in the ﬁeld of
hyperpolarized 13C MRS. The overall pattern in the relation between
18F FDG uptake and lactate generation (linear relation between mea-
sures for sarcoma but not carcinoma, higher ratio of lactate generation
to 18F FDG uptake in sarcoma as compared to carcinoma, Fig. 3a, b) was
reproduced by measurements based on single time point 13C MRS
imaging (Fig. 4). This supports the robustness of the ﬁndings. The tu-
mors of the present study showed a large heterogeneity of anatomic
location which could inﬂuence delivery of the hyperpolarized pyruvate
substrate; however the delivery times were not diﬀerent between tumor
types. Lactate can also be detected by 1H MRS [9] but hyperpolarized
13C MRS provides information on the dynamics of lactate generation,
which may be advantageous in the assessment of alterations of tumor
cell energy metabolism [33]. Dynamic acquisition of FDG-PET with
arterial blood sampling, which would have enabled kinetic modelling of
FDG uptake, was not feasible with the present patient setup. Overall,
signiﬁcant correlations of pyruvate-to-lactate rate constants and 18F
FDG uptake appear irrespective of FDG uptake time (Fig. 3 and
Table 2), suggesting that kinetic modelling would not alter the con-
clusions of the study.
We may speculate on why the ratio of lactate generation and 18F
FDG uptake was diﬀerent for sarcoma and carcinoma in context of the
origin of the Warburg eﬀect. The aerobic glycolysis generally exhibited
by cancer cells can occur while the cells still use glucose to produce ATP
in the mitochondria [8,24,25,29]. Accordingly, the relative contribu-
tion of aerobic glycolysis and oxidative phosphorylation may vary
[24,26]. Therefore, the diﬀerent relation between 18F FDG uptake and
lactate generation in diﬀerent cancer tissue types may be interpreted as
a metabolic signature of the relative contribution from the Warburg
eﬀect. If this interpretation can be conﬁrmed by independent experi-
ments including ex vivo validation, the relation between 18F FDG up-
take and lactate generation may be used to shed further light on the
origins of the Warburg eﬀect [30,31].
From a clinical perspective, the question naturally arises whether
18F FDG PET and [1-13C]pyruvate MRSI provides similar or com-
plementary information. Based on the present study we can hypothesize
that the combination of 18F FDG PET and hyperpolarized [1-13C]pyr-
uvate MRSI (hyperPET), but not the modalities alone, can characterize
regulation of glycolysis. Reprogramming of energy metabolism has
been proposed as a Hallmark of Cancer [32] and thus hyperPET may
provide a new method of better metabolic cancer phenotyping. How-
ever, a possible clinical role of such improved phenotyping by hy-
perPET will need to be investigated in future human studies.
HyperPET data from six of the canine cancer patients included here
was already reported by our group in [20,22]. However, due to the
small number of animals the cross-sectional comparison of 18F FDG PET
and 13C MRS as presented here was not attempted.
The present study population showed a large heterogeneity of
cancer types, lactate generation rate and 18F FDG uptake. Such het-
erogeneity is also a common feature of clinical cancer patients and was
likely beneﬁcial to explore main diﬀerential characteristics of 18F FDG
PET and hyperpolarized 13C MRS. However, the heterogeneity together
with low to intermediate grades hampered a comparison between
cancer grade and imaging ﬁndings. The correlation of FDG uptake and
apparent pyruvate-to-lactate rate constants was evaluated grouping
patients according to main cancer tissue types (carcinoma, sarcoma).
While soft tissue sarcoma and bone sarcoma appeared to follow a
common trend line, this very rough classiﬁcation may be the reason
why no correlation was observed for the group of carcinoma patients.
Clearly, with the small number of animals and the limited number
of cancer tissue types, the present data should be viewed as hypothesis
generating only. Overall, combined PET/MRI using 13C hyperpolarized
probes seem valuable to improve metabolic phenotyping in cancer.
5. Conclusion
Comparing 18F FDG PET and 13C MRS apparent pyruvate-to-lactate
rate constants we found correlation within certain tumor tissue types
but not across tumor types. As 13C MRS apparent pyruvate-to-lactate
transfer most likely is the best reﬂection of aerobic glycolysis (Warburg
Fig. 5. Group diﬀerences of FDG uptake and lactate generation.
Diﬀerences of SUVmean (subﬁgure a), apparent pyruvate-to-lactate transfer coeﬃcient kPL (subﬁgure b) and kPL/SUVmean (subﬁgure c) between groups of carci-
noma and sarcoma patients are illustrated. Only kPL/SUVmean shows a signiﬁcant group diﬀerence (p-values are reported in Table 3). All PET data are obtained
nominally 60min p.i. Symbols are the same as in Figs. 3 and 4.
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eﬀect) this demonstrates that 18F FDG PET cannot in general be re-
garded as a clear indicator of the Warburg eﬀect, but within certain
tumor tissue types and microenvironment conditions there may be a
strong correlation. The diﬀerences between the two modalities may
allow for better metabolic phenotyping performing hybrid imaging in
the form of hyperPET.
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